Advertisement
Pharma Business – February 12, 2025
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).
Collaboration – February 11, 2025
All participants are determined to establish Europe as a global leader in Artificial Intelligence (AI), advancing AI development and application.
Acquisition – February 10, 2025
Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation in a carve-out transaction from Mitsubishi Chemical Group Corporation.
New Market – February 10, 2025
Boule Diagnostics has entered into an exclusive distribution agreement with VitalScientific for the US market.
Business Award – February 10, 2025
Evelina Vågesjö has been appointed an Eisenhower Fellow together with 24 other exceptional mid-career leaders from five continents for its prestigious 2025 Global Program.
Financing – February 7, 2025
The company has carried out an offering of new shares in a directed share issue to institutional and other qualified investors and raises gross proceeds of EUR 5.2 million.
Clinical Trials – January 29, 2025
Herantis Pharma has announced an update of the ongoing Phase 1b clinical trial of HER-096.
Clinical Trials – January 14, 2025
Orexo has announced positive topline results from the clinical study OX640-002.
Clinical Trials – December 18, 2024
Hansa Biopharma has announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.
Clinical Trials – December 11, 2024
Immunovia has announced the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).
Clinical Trials – December 10, 2024
The first dose has been administered in the company’s Phase II clinical study evaluating the drug candidate sevuparin for the treatment of chronic kidney disease (CKD) with associated anemia.
Clinical Trials – December 3, 2024
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.
Acquisition – February 5, 2025
The acquisition of CRST fully aligns with the strategy of LINK Medical to strengthen its position in the Nordic market, it states.
CDMO – February 4, 2025
The two companies have announced a strategic alliance to collaborate on the manufacturing of current pipeline programs and potential future programs based on Eleva’s technology platform.
Pharma Business – February 3, 2025
AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
Acquisition – February 7, 2025
Mayumana Healthcare is a specialist distributor of medical equipment and related supplies in the Netherlands.
Agreement – February 3, 2025
“We are thrilled to announce this strategic partnership with a top-tier medical school in clinical and radiological research. This is a critical step toward our vision of developing multiple products within data quality and liver disease management,” says Gerald Pötzsch, CEO of ContextVision.
MedTech Business – February 3, 2025
The US Food and Drug Administration (FDA) has granted clearance for the surgical device SutureTOOL.
Biotech Business – February 5, 2025
The company has resumed development of the its TAK1 program as the company has regained the control and ownership of the program.
Biotech Business – February 4, 2025
The funding round was led by new investors Fåhraeus Startup and Growth (FSG), a Nordic venture capital fund, and European Innovation Council (EIC) Fund.
Acquisition – January 31, 2025
WntResearch has entered into an agreement for the acquisition of all shares in the Swedish privately owned company OPSY for a purchase price of approximately SEK 120 million, to be paid with newly issued shares in WntResearch.
Science article – February 7, 2025
Researchers at Linköping University have succeeded in creating a close connection between individual cells and organic electronics.
Science Award – January 30, 2025
The Crafoord Prize in Polyarthritis 2025, worth SEK six million, is awarded to Christopher Goodnow, Australia, and David Nemazee, USA.
Science News – January 16, 2025
A new international study led by researchers at Karolinska Institutet shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images.
Diamyd
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd® is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes.
Stryker
The Senior Operative ensures that the Stryker products are received, stored and shipped in a professional and timely fashion with the right quality.
Stryker
Are you ready to make a real impact in healthcare? At Stryker, we’re passionate about improving patient outcomes and enhancing hospital experiences.
Stryker
Are you ready to make a real impact in healthcare? At Stryker, we’re passionate about improving patient outcomes and enhancing hospital experiences.
Stryker
Are you ready to make a real impact in healthcare? At Stryker, we’re passionate about improving patient outcomes and enhancing hospital experiences.
ArgusEye
An opportunity to use your strategic mindset and sales expertise to make a transformative impact in the biopharmaceutical industry.
In a new job – January 28, 2025
The LINK Medical Board has announced the appointment of Anders Göransson as the new CEO of LINK Medical.
In a new job – January 20, 2025
Vedran Beglerbegovic is appointed as the new CEO of SyntheticMR.
In a new job – January 14, 2025
Mikko Kemppainen has been appointed as General Counsel and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group as of 1 June 2025.
Careers article – January 9, 2025
Getting back to work after a long and relaxing holiday can be quite hard. Here is some advice to make things easier.
Biotech Business – December 3, 2024
Alligator Bioscience is sharpening its primary focus on its lead asset mitazalimab, and, given current capital restraints, plans to adjust the size of its organization and scope of operations to reflect that.
Biotech Business – November 26, 2024
The rightsizing is expected to result in redundancy of approximately 20 percent of the employees across the CELLINK organization.
Profiles in Business – February 13, 2023
Iris Öhrn considers herself a cosmopolitan person, and with good reason. The investment advisor for life science at Business Region Göteborg left her native Cuba to study and work abroad before settling in Sweden. While up until recently, most of Iris Öhrn’s goals were professional, now she is seeking to have more of an impact […]
Profiles in Business – December 16, 2021
An adventurous spirit rooted in a Viking heritage and her parents’ as an example helped spur Gitte Pedersen to move from her native Denmark to the U.S. 20 years ago, where she helped create a company and made a home. CEO and co-founder of Genomic Expression in Massachusetts, USA, Gitte Pedersen also credits her mother […]
Profiles in Business – December 15, 2019
Business woman Barbro Ehnbom has become renowned for her valuable networks and her successful business-generating activities and within life sciences she is perhaps best known as the founder of SALSS, the Swedish-American Life Science Summit.
This site uses cookies
